CAR T-Cell Therapy: Overcoming Toxicities

Following the success of the first checkpoint inhibitors for treating cancer, many researchers are now turning their attention to chimeric antigen receptor (CAR) T cell therapy. This novel treatment makes use of a cancer patient’s own T cells, which are removed and modified so that they can better recognize and attack cancer cells. These modified cells are then infused back into the patient’s body. While this approach has shown some success for certain cancers, severe toxicities have limited its widespread application. Researchers are attempting different methods to overcome these toxic effects, including using gene-editing tools such as CRISPR to modify CAR T cell protein production and employing antibody therapy to potentially block toxicity-inducing proteins. Will CAR T cell therapy emerge as a game changer for cancer treatment? Or are the hurdles too high? Join The Scientist for an educational webinar, sponsored by Enzo, Nanostring, Sartorius, and IsoPlexis as we explore CAR T cell therapy research and gain insight into the next steps.

Topics to be Covered

Diagnosing and managing CAR T cell therapy-related toxicities
Identifying early predictive toxicity markers in patients treated with CAR T cell therapy

Event Overview

Register Now

CAR T-Cell Therapy: Overcoming Toxicities